DOI: 10.1016/j.conctc.2020.100607; PMCID: PMC7334572
Nearly all individuals with Down Syndrome (DS) display pathology associated with Alzheimer's disease (AD) beginning as early as age 30. Previous research in typically developed adults suggests that increased moderate-to-vigorous physical activity (MVPA) may improve cognitive function and protect against age-related structural and functional changes in the brain; however, the potential impact of increased MVPA on the development of AD in adults with DS has not been evaluated. Despite the potential positive impact of MVPA on cognition and AD risk, participation in MVPA among young adults with DS is low. The limited research evaluating strategies for increasing MVPA in adults with DS has been unsuccessful in increasing MVPA. Results from our preliminary investigation where we remotely delivered real-time MVPA, led by a trained health educator, to groups of adults with DS in their homes via video conferencing on a tablet computer demonstrated high attendance, increased MVPA during group sessions, and improvements in cognitive function. However, the sustainability, impact on total daily MVPA, optimal session frequency, and potential impacts on cognitive function and brain health of remotely delivered group MVPA sessions in adults with DS are unknown. Therefore, we will conduct a trial in 80 non-demented adults with DS to determine the feasibility and potential efficacy of remotely delivered group MVPA sessions to increase daily MVPA, relative to a usual care control. Secondarily we will assess the impact of MVPA on cardiovascular fitness, quality of life, cognitive function and brain parameters related to AD.
NCT registration: NCT04048759.
Contemp Clin Trials Commun
AD, Alzheimer's Disease; Alzheimer's disease; Cognition; DS, Down Syndrome; Down syndrome; MVPA, moderate to vigorous physical activity; Physical activity; RH, remote high; RL, remote low; Technology; UC, Usual Care
Ptomey LT, Szabo-Reed AN, Martin LE, et al. The promotion of physical activity for the prevention of Alzheimer's disease in adults with Down Syndrome: Rationale and design for a 12 Month randomized trial [published correction appears in Contemp Clin Trials Commun. 2020 Dec 10;20:100690]. Contemp Clin Trials Commun. 2020;19:100607. Published 2020 Jun 30. doi:10.1016/j.conctc.2020.100607